Network meta-analysis suggested that, when compared with the control groups (OR 0.74, 95% CI 0.62–0.87), GLP-1 agonists (OR 0.76, 95% CI 0.59–0.96) and with DPP-4 inhibitors (OR 0.67, 95% CI 0.50–0.86), SGLT-2 inhibitors were associated with a lower risk of acute kidney injury events (Fig 4) The comparison of control groups versus SGLT-2 inhibitors, DPP-4 inhibitors and GLP-1 agonists had the major contribution in entire networks, with 32.9%, 32.1% and 32.8% for AKI events, respectively (Appendix 3 in S1 Text). This evidence concerns the gene GLP1R and acute kidney injury.